The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

This publication has 111 references indexed in Scilit:

• Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
  Journal of Thoracic Oncology, 2012
• Germline BAP1 mutations predispose to malignant mesothelioma
  Nature Genetics, 2011
• Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis
  PLOS ONE, 2011
• Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes
  Journal of Biological Chemistry, 2010
• Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
  Lung Cancer, 2010
• Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortex
  Trends in Cell Biology, 2009
• Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
  Journal of Thoracic Oncology, 2009
• Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma
  Journal of Thoracic Oncology, 2008
• Mesothelin targeted cancer immunotherapy
  European Journal of Cancer, 2008
• Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
  Thorax, 2007